Goodwin Procter LLP advised Morningside Ventures on the deal. Morningside Ventures led Immune Regulation’s Series B funding round alongside existing shareholders including London based 24Haymarket. The…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
